Artiva Biotherapeutics (ARTV) Other Accumulated Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Other Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 25.99% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 25.99% increase from a year earlier, with the FY2025 full-year figure at $73000.0, down 95.04% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.1 million, up from $73000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for ARTV reached as high as $2.9 million in Q4 2023 and fell as low as $73000.0 in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $1.1 million across 4 years, with a median of $973000.0 in 2025.
• Across the five-year window, Other Accumulated Expenses slumped 95.04% in 2025 and climbed 25.99% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $2.9 million in 2023, then slumped by 48.55% to $1.5 million in 2024, then slumped by 95.04% to $73000.0 in 2025, then surged by 1341.1% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $1.1 million in Q1 2026, $73000.0 in Q4 2025, and $442000.0 in Q3 2025.